EUROPEAN BIOTECHS RAISE $2 BIL. IN FINANCING IN 1996, QUINTUPLING 1995 LEVEL; FRENCH, GERMAN BIOTECH HEATS UP ON HEELS OF MATURE U.K. INDUSTRY
Executive Summary
The amount of capital raised by the European biotechnology industry in 1996 grew four-fold over 1995 levels, Ernst & Young calculates in its fourth annual report on the European biotech industry. The report, entitled "European Biotech `97: A New Economy," was released April 22 at an Ernst & Young/Atlas Ventures life sciences conference in Amsterdam.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth